UBS Group AG Acquires 17,687 Shares of Zoetis Inc. $ZTS

Key Points

• UBS Group AG increased its stake in Zoetis by 0.6%, buying 17,687 shares to hold 2,827,318 shares (~0.64%) valued at $355.7M; institutional investors own 92.8% of ZTS, with Vanguard adding 5.47M shares to hold 47.78M shares ($6.01B).
• Recent results and guidance: Zoetis beat Q expectations with EPS of $1.48 vs. $1.40 and revenue of $2.39B (up 3% YoY), and set FY2026 EPS guidance of $7.00–$7.10 (consensus ~7.02).
• Dividend and valuation: Zoetis declared a $0.53 quarterly dividend ($2.12 annual, 1.8% yield, ex-dividend Apr 20), trades at a $49.6B market cap with a P/E of 19.6, and carries a consensus analyst rating of "Hold" with a $152.25 price target.

UBS Group AG lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 0.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,827,318 shares of the company's stock after acquiring an additional 17,687 shares during the period. UBS Group AG owned approximately 0.64% of Zoetis worth $355,733,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock worth $622,222,000 after purchasing an additional 2,179,578 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company's stock worth $631,046,000 after purchasing an additional 550,859 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Zoetis by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company's stock worth $620,595,000 after purchasing an additional 496,320 shares in the last quarter. Finally, Fundsmith LLP increased its position in shares of Zoetis by 25.3% during the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company's stock worth $528,966,000 after purchasing an additional 730,300 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Zoetis stock opened at $117.85 on Tuesday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The stock has a market cap of $49.57 billion, a price-to-earnings ratio of 19.58, a P/E/G ratio of 1.78 and a beta of 0.98. The business's 50-day simple moving average is $120.65 and its 200 day simple moving average is $125.10. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 7.02 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis's payout ratio is 35.22%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. Piper Sandler reiterated a "neutral" rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. UBS Group set a $136.00 target price on shares of Zoetis in a research report on Thursday, January 29th. BTIG Research reiterated a "buy" rating and set a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. Finally, William Blair reiterated an "outperform" rating on shares of Zoetis in a research report on Monday, March 2nd. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $152.25.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.